RGNX: $7 Stock Sitting on a $1.38B AbbVie Deal
RGNX stock analysis: 400% revenue growth & $1.38B catalyst — full deep dive
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down REGENXBIO Inc. (RGNX) and its $1.38 billion AbbVie collaboration, proprietary NAV gene therapy platform, and pivotal Phase 3 clinical catalysts. With Q2 2026 revenue growing over 405% year-over-year and shares trading at an Enterprise Value of just 2.0 times revenue, the key question for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.